These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 33655822)

  • 1. Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies.
    Ali AH; Younis N; Abdallah R; Shaer F; Dakroub A; Ayoub MA; Iratni R; Yassine HM; Zibara K; Orekhov A; El-Yazbi AF; Eid AH
    Curr Med Chem; 2021; 28(36):7427-7445. PubMed ID: 33655822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
    Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
    Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
    Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
    Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
    Dugré N; Lindblad AJ; Perry D; Allan GM; Braschi É; Falk J; Froentjes L; Garrison SR; Kirkwood JEM; Korownyk CS; McCormack JP; Moe SS; Paige A; Potter J; Thomas BS; Ton J; Young J; Weresch J; Kolber MR
    Can Fam Physician; 2023 Oct; 69(10):701-711. PubMed ID: 37833094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
    Reklou A; Katsiki N; Karagiannis A; Athyros V
    Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LDL-cholesterol reduction in chronic kidney disease: options beyond statins.
    Goonasekera MA; Mafham MM; Haynes RJ
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):480-488. PubMed ID: 32701596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Khan SU; Rahman H; Okunrintemi V; Riaz H; Khan MS; Sattur S; Kaluski E; Lincoff AM; Martin SS; Blaha MJ
    J Am Heart Assoc; 2019 Apr; 8(7):e011581. PubMed ID: 30898075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
    Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
    Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
    Rached F; Santos RD
    Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol-Lowering Agents.
    Rosenson RS; Hegele RA; Koenig W
    Circ Res; 2019 Feb; 124(3):364-385. PubMed ID: 30702994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.